A carregar...

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

Aripiprazole has been approved by regulatory agencies for the treatment of schizophrenia and bipolar I disorder. Although it is a dopamine partial agonist, it also has substantial binding affinity for the serotonin 5HT2A receptor. Several double-blind randomized clinical trials have established the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Citrome, Leslie
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2006
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2671949/
https://ncbi.nlm.nih.gov/pubmed/19412492
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!